Rockville, Md. (August 5, 2024) – Cellphire Therapeutics, Inc., a clinical stage biotechnology company developing next-generation allogeneic cellular therapeutics, announced today that Damien Bates, MD, PhD, FRACS, MBA joined the company as Chief Medical Officer.
Cellphire Therapeutics is excited to announce the appointment of Dr. Damien Bates as Chief Medical Officer. Dr. Bates brings a wealth of experience in clinical development and strategic leadership to the role. In his new position, Dr. Bates will spearhead both strategic initiatives in clinical development and daily clinical operations, driving forward the company’s vision of saving lives with transformative stabilized cellular therapeutics. His track record of success in the clinical development and regulatory approval of multiple allogeneic cell therapies, key opinion leader engagement and operational excellence will be instrumental in advancing Cellphire's innovative pipeline and ensuring the successful execution of its clinical programs. We are thrilled to welcome Dr. Bates to the team and look forward to the impact of his expertise on our continued growth and success.
Mike Gaffney, CEO of Cellphire Therapeutics, shared “I am delighted to welcome Dr. Damien Bates to our leadership team. His extensive experience in biologic product drug development, clinical trial execution, regulatory engagement and commercial experience adds to our team’s breadth and depth. Importantly, his experience as a surgeon treating patients suffering from trauma and life-impacting injury creates a personal understanding of the unmet needs our products address. The team and I are excited to have Damien as a key leader in advancing the development of our innovative therapies and getting our products in the hands of clinicians. We are confident that Dr. Bates’ leadership will drive significant progress and strengthen our position in the field.”
Mike Gaffney, CEO of Cellphire Therapeutics, shared his thoughts on the transition of Dr. Allan Alexander to an advisory role “Damien’s joining Cellphire is bittersweet. As we welcome Dr. Damien Bates to our team, we also want to extend our deepest gratitude to Dr. Allan Alexander for his invaluable contributions to Cellphire. While Allan steps away from his current role to take care of family members, we are fortunate that he will continue to play an important role advising me and our executive team in progressing our products through the clinic to licensure. Allan’s passion for our patients and belief in the potential of our products to save lives is unwavering. His advice and counsel remain crucial as we move forward.”
About Cellphire Therapeutics
Cellphire Therapeutics, Inc. is a biotechnology company developing next-generation allogeneic, platelet derived, cellular therapeutics. Cellphire is applying its proprietary technologies to develop lifesaving products. With two hemostatic products in Phase 2 clinical development, Cellphire’ s technologies address significant unmet needs for hemostatic therapeutics. Across the range of geographies, clinical settings and indications. These include rural and 3rd world use, Orphan populations, perioperative use for surgery and trauma, and brain hemorrhage. For more information, visit Cellphire Therapeutics at www.Cellphire.com.
Contact Information:
Robert Woods
VP, Business Operations
RWoods@Cellphire.com